India's weight-loss drug market is delivering a sobering lesson to the global pharmaceutical industry about market expectations. Despite large-scale generic production of GLP-1 medications and prices dropping to $14 per month, sales performance has fallen far short of forecasts, revealing deeper cultural, social, and regulatory barriers that transcend pricing.
As of July this year, over thirty generic GLP-1 drugs have been launched in Indian pharmacies. Nomura Holdings had projected sales of $261 million for these medications by 2026, yet according to research firm Pharmarack Technologies, actual sales through July this year stand at only about 20% of that forecast.
The tepid market response is directly undermining the pharmaceutical industry's growth bets on India. An executive at Novo Nordisk (manufacturer of Wegovy and Ozempic) indicated that manufacturers are increasingly concerned about the slow pace of market adoption.
Pharmarack Vice President Sheetal Sapale stated bluntly, "Exponential growth will not happen, and there is now a realistic understanding of the market's actual size among all parties involved."
Price Advantage Fails to Convert into Demand
India was widely viewed as a critical testing ground for expanding GLP-1 drugs beyond the US and Europe. With a population of 1.4 billion, India ranks second globally in obesity numbers after the US and China, while also being the world's second-largest diabetic population. Metabolic conditions such as thyroid disorders and fatty liver disease are also rising rapidly.
In March this year, Indian patents for the active ingredients in Ozempic and Wegovy expired, allowing generics to flood the market at prices as low as $14 per month, theoretically making these drugs affordable for hundreds of millions of potential patients.
However, the price decline has not translated into a sales surge. Pune-based diabetes and obesity researcher Chittaranjan Yajnik noted, "Drug acceptance depends on generational history, local culture, geographical conditions, and the socioeconomic group patients belong to. It is not merely a matter of price."
Cultural Perceptions Create Hidden Resistance
India's complex cultural attitudes toward obesity constitute a hidden barrier to drug promotion. Kubera, the god of wealth in Hindu tradition, is often depicted with a large belly, symbolizing abundance and good fortune.
Vandita Morarka, founder of the non-profit One Future Collective, explained that body weight in India "is a marker of affluence. It means you have enough to eat in a country that has experienced severe poverty, droughts, and malnutrition. It is a symbol of status."
Simultaneously, obesity is paradoxically viewed as a personal failure of willpower, and this contradictory mindset drives patients to conceal their treatment. Saloni Paliwal, co-founder of weight-loss platform Voy India, noted that the stigma around injection-based weight-loss drugs stems from the perception that "you are taking a shortcut. You should do it the hard way like everyone else - hit the gym, eat less." Patients are even discussing in WhatsApp groups and Reddit threads how to inject discreetly and how to refrigerate medications without family members knowing.
Female Patients Face Additional Obstacles
Women constitute the vast majority of weight-loss drug users in major markets, but Indian women - particularly those in traditional households - often lack autonomous decision-making power over medical spending. Medication decisions frequently require approval from husbands, parents, or in-laws.
Mumbai-based physician Swati Pradhan shared, "My patients often come to me and say they have only saved enough money for about three months, and ask me to accelerate their treatment course."
Additionally, the widespread circulation of misinformation is intensifying patient doubts. Jennifer Joseph, a 33-year-old IT professional from Pune, said that during her treatment, her parents were worried because they did not understand the therapy, while friends constantly forwarded her news about counterfeit drugs, severe side effects, and complication cases. "I won't lie, it did scare me too. When you keep seeing negative headlines, it becomes easy to start questioning your own decisions."
Regulatory Restrictions Hamper Marketing Efforts
Pharmaceutical companies also face strict Indian legal restrictions on drug advertising. To circumvent the direct-to-consumer drug advertising ban, Eli Lilly launched a public health awareness campaign during a high-profile cricket tournament in February, promoting obesity as a disease and encouraging people to seek medical care. While the advertisements did not mention Lilly's GLP-1 medications, they prominently featured the company's name.
However, Indian drug regulatory authorities suspended the weight-loss related promotional activities in March, determining that such efforts amounted to disguised direct advertising. The campaign content remains accessible online, but the outdoor billboards directing users have been removed.
Long-Term Engagement Replaces Short-Term Surge Expectations
These challenges are prompting the industry to reassess its strategy for promoting GLP-1 drugs in India and other emerging markets.
Mumbai-based diabetes specialist Rajiv Kovil believes pharmaceutical companies need to help patients better understand these medications and may need to offer supplementary services such as nutritional supplements to enhance patient acceptance of GLP-1 therapies. "Generics were expected to disrupt the market, but that has not happened," he said. "This will be a much longer game."
The Indian market experience demonstrates that for pharmaceutical companies seeking to replicate the GLP-1 success story globally, lowering prices is a necessary condition, but truly opening the market requires navigating a complex web of cultural, social, and regulatory factors.
Comments